
The pharmaceutical company, Kymab, has appointed the former Chief Scientific Officer in Zealand Pharma, Christian Grøndahl, as its new CEO.
Under the leadership of Christian Grøndahl the company plans to further develop its platform and advance several drug candidates to clinical development stage over the next five years.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app